Exclusive Summary

• • No IP barriers: Original Unasyn patents expired long ago; open, fully genericized markets globally.
• • Broad hospital use-cases: Effective for bite wounds, mixed aerobic–anaerobic infections, obstetric/gynecologic infections, diabetic foot/SSTI, and aspiration-related pneumonia.
• • Guideline-aligned: Recommended by multiple national/international guidelines and widely stocked as an essential hospital injectable antibiotic.
• • Supply reliability wins: Periodic global shortages in beta-lactam/BL-BLI classes create entry points for quality-assured, on-time suppliers.
• • Cost-competitive: Typically 80–95% below originator; tenders in LMICs often <US$1 per 1.5 g vial; OECD hospitals ~US$2–6/vial.